Intangible Assets (Tables)

9 Months Ended

Sep. 30, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets Net

Intangible assets as of September 30, 2018 and December 31, 2017 consists of the following:

	Useful Life	Gross Carrying Cost		Accumulated Amortization			Impairment Loss		Net Book Value
September 30, 2018
DermaWand® Purchase	5 years	$	1,163,816	$	(800,725	)	$	-	$	363,091
PhotoMedex Patented/Unpatented Technology	5 years		940,628		(313,540	)		-		627,088
PhotoMedex Trademarks	5 years		1,100,000		(366,667	)		-		733,333
Total		$	3,204,444	$	(1,480,932	)	$	-	$	1,723,512

	Useful Life		Gross Carrying Cost		Accumulated Amortization			Impairment Loss			Net Book Value
December 31, 2017
Ermis Labs Formulations/ Trademarks	5 years	$	1,512,443	$	(277,281	)	$	(1,235,162	)	$	-
DermaWand® Purchase	5 years		1,163,816		(581,673	)		-			582,143
PhotoMedex Patented/Unpatented Technology	5 years		940,628		(172,447	)		-			768,181
PhotoMedex Trademarks	5 years		1,100,000		(201,667	)		-			893,333
Total		$	4,716,887	$	(1,233,068	)	$	(1,235,162	)	$	2,248,657

Schedule of Finite-lived Intangible Assets, Future Amortization Expense

The following table outlines the estimated future amortization expense related to the intangible assets held as of September 30, 2018:

2018 (remaining three months)	$	175,000
2019		699,000
2020		408,000
2021		408,000
2022		34,000
Total	$	1,724,000